AZD 2184
Alternative Names: [11C]AZD 2184; AZD2184Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Aminopyridines; Benzothiazoles; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Sweden (IV)
- 26 Jun 2013 Navidea Biopharmaceuticals secures loan ($US25 million) from GE Capital, Healthcare Financial Services to support development of the company's pipeline and for other purposes
- 15 Jan 2013 AZD 2184 licensed to Navidea Biopharmaceuticals